Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Sees Studies on Preventive Effect as a “Must” for Coronavirus Vaccines: Official
October 21, 2020
- Keidanren Calls for Clearer Classification Criteria for “Software as a Medical Device” to Promote Development
October 21, 2020
- Vice Health Minister Vows to Work on Law Amendment to Set Up Sound Vaccination Scheme
October 20, 2020
- Japan Cannot Boast of Its Development Status of COVID-19 Vaccines/Drugs: LDP Health Committee Chair
October 20, 2020
- 3 Mega Pharma-Drugs Now Approved in Japan with Continuous Manufacturing, Japan Players Could Follow Suit Soon: PMDA Specialist
October 19, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Up for PAFSC Review on Oct. 30
October 19, 2020
- Japan’s Conditional Approval System for Regenerative Meds Is “Patient-Centered System”: PMDA Exec
October 19, 2020
- Japan Needs to Consider Legal Positioning of Stable Drug Supply Rules: Official
October 19, 2020
- LDP’s Health Committee OKs Bill to Amend Immunization Act
October 16, 2020
- Forxiga’s Heart Failure Use Up for PAFSC Discussion on October 29
October 16, 2020
- PMDA Gets Nearly 10 Requests for Free COVID-19 Vaccine Consultations in 2 Weeks
October 15, 2020
- MHLW to Make “Comprehensive Decision” on Off-Year Drug Pricing Plan: Minister
October 15, 2020
- MHLW Revises Leaflets on HPV Vaccination, Issues Related Notification
October 13, 2020
- Make Temporary Measure Permitting Telemedicine Permanent: Reform Panel Members
October 12, 2020
- MHLW to Reexamine Whether to Permit Sale of Emergency Contraceptives Without a Prescription
October 12, 2020
- Opdivo under PMDA Risk Review for Fulminant Hepatitis
October 12, 2020
- List of MOF’s Proposals Related to Pharmaceuticals
October 9, 2020
- MOF Calls for Setting New Targets for Generic and Biosimilar Use
October 9, 2020
- MHLW to Revise Immunization Act to Allow Govt to Shoulder Liability Risks for COVID-19 Vaccines
October 9, 2020
- MOF Pitches Off-Year Re-Pricing for “All Products” Including Patented Meds, Eyes Adjustment Rate Revision Too
October 9, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…